Investigating the impact of particle manufacturing process on nanomedicine biological fate
Dr Z Rattray
Prof Y Perrie
No more applications being accepted
Funded PhD Project (European/UK Students Only)
A new drug candidate faces multiple challenges during its development, and in oncology drug development, a key challenge is achieving the balance between efficacy and off-target toxicity.
Nanomedicines have emerged as a promising solution to tackling such challenges.
The nanoparticle manufacturing process is known to impact product physicochemical characteristics that in turn influence their quality and biological fate. By understanding the impact of such process, a quality by design approach can be used in the manufacture of nanomedicines.
The aim of this project is to evaluate how nanoparticle manufacture processes impact product characteristics, and how these characteristics impact nanomedicine biological interactions. The successful candidate will manufacture nanoparticles with varying physicochemical attributes, apply novel orthogonal cutting-edge analytical techniques for particle characterization, and measure particle interactions with plasma and serum biomolecules. This PhD project will be highly-suited to candidates from a pharmaceutical sciences, chemistry, or engineering background who are keen to develop skills in formulation and analytical chemistry.
This prestigious and highly-competitive project is in collaboration with the National Physical Laboratory (NPL), where you will be part of the Postgraduate Institute for Measurement Science (PGI). NPL is the UK National Measurement Institute and a world-leading centre for measurement science and technology.
By joining this collaborative project, you will benefit from a world-class interdisciplinary research programme in drug delivery, formulation, microfluidics, and particle metrology. As a PhD candidate at Strathclyde, you will have access to the Strathclyde Researcher Development programme (PG Cert) offering you a competitive advantage as a research professional. Our campus is based in the very heart of Glasgow.
How to Apply:
Applicants must have obtained, or expect to obtain, a first or 2.1 UK honours degree, or equivalent for degrees obtained outside the UK, in pharmaceutical sciences, engineering, or analytical chemistry.
All enquiries and applications should be directed to Dr Zahra Rattray ([Email Address Removed]). Applications will be reviewed when received, and shortlisted candidates will be invited for an interview. The position will remain open till the advertised deadline.
All applications must be submitted via email (subject line: PhD applicant) as a single pdf file and include the following:
1) A cover letter (max 1 page) explaining your interest and fit to the project
2) A CV (maximum three pages).
3) Names and contact details of TWO references (including email addresses).
4) A copy of your academic transcripts.
Subject line: PhD applicant
Successful candidates will be invited for an interview in April 2020. It is anticipated that the successful candidate will start in summer 2020.
The studentship will last for 3.5 years. It will cover the tuition fee for UK/EU candidates, and provide and annual tax-free PhD stipend (starting £15,000 per annum). Please note that candidates outside the EU will not be eligible for funding under this studentship. Only EU candidates with settled status may apply.
Barbero F, Russo L, Vitali M, et al. Formation of the Protein Corona: The Interface between Nanoparticles and the Immune System. Seminars in Immunology 2017;34: 52-60.
Bertrand, N., et al. (2017). "Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics." Nature Communications 8(1): 777.
Hamrang (Rattray), Z., et al. (2015). "Characterisation of Stress-Induced Aggregate Size Distributions and Morphological Changes of a Bi-Specific Antibody Using Orthogonal Techniques." Journal of Pharmaceutical Sciences 104(8): 2473-2481.
Rattray Z, Rattray NJW, Pluen A (2014). Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation. Trends in Biotechnology 31(8):448-58.